M. Savin

发表

Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.

F. Holmes, J. O’Shaughnessy, Stephen E. Jones, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Synchronization of converging metabolic pathways: activation of the Cystathionine gamma-synthase of Neurospora crassa by methyltetrahydrofolate.

J. Selhub, M. Savin, W. Sakami, 1971, Proceedings of the National Academy of Sciences of the United States of America.

Yttrium-90 radioembolization of malignant tumors of the liver: gallbladder effects.

A. Sag, M. Savin, Nirish R. Lal, 2014, AJR. American journal of roentgenology.

Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging.

R. Salem, C. Wong, R. Lewandowski, 2005, Journal of vascular and interventional radiology : JVIR.

Breast Cancer Occurring after Childhood Total Body Irradiation as Conditioning for Allogeneic Stem Cell Transplantation: Case Report and Review of the Literature

M. Savin, 2016 .

Safety and Efficacy of Radioembolization in Elderly (≥ 70 Years) and Younger Patients With Unresectable Liver-Dominant Colorectal Cancer.

C. Nutting, S. Rose, Steven J. Cohen, 2016, Clinical colorectal cancer.

Updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases.

C. Nutting, S. Rose, D. Coldwell, 2017, Journal of gastrointestinal oncology.

Unresectable colorectal cancer liver metastases treated with radioembolization: Updated survival analysis of the MORE study.

C. Nutting, S. Rose, D. Coldwell, 2017 .

Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies

V. Gebski, P. Gibbs, F. Lammert, 2018, Clinical colorectal cancer.

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.

F. Holmes, J. O’Shaughnessy, J. Pippen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor-to-normal particle deposition ratio in primary versus secondary liver malignancies: impact on tumor dose and radioembolization treatment planning

M. Savin, S. Emerson, D. Goldin, 2014 .

Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non-Small Cell Lung Cancer Treatment Setting.

M. Socinski, R. Salgia, B. Polite, 2018, Journal of clinical pathways : the foundation of value-based care.

Yttrium-90 Infusion: Incidence and Outcome of Delivery System Occlusions during 885 Deliveries.

M. Chehab, C. Wong, M. Savin, 2015, Journal of vascular and interventional radiology : JVIR.

Y-90 microsphere therapy: prevention of adverse events.

D. Bakalyar, M. Savin, Janice M Campbell, 2008, Cancer biotherapy & radiopharmaceuticals.

Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors.

S. Nag, S. Sapareto, C. Nutting, 2009, International journal of radiation oncology, biology, physics.

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab

M. Savin, A. Kaempf, Z. Mitri, 2021, BMC Cancer.

Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel.

N. Robert, J. O’Shaughnessy, J. Pippen, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mechanical Thrombectomy in Pulmonary Embolism Associated with COVID-19: A “Clotography” Gallery

M. Savin, T. Bowers, H. Kado, 2021, Vascular and endovascular surgery.

Prediction of chemotherapy response in human leukemia using an in vitro chemotherapy sensitivity test on the leukemic colony-forming cells.

B. Hoogstraten, M. Savin, C. Park, 1980, Blood.

Improved growth of in vitro colonies in human acute leukemia with the feeding culture method.

B. Hoogstraten, M. Savin, C. Park, 1977, Cancer research.

Safety and efficacy of resin 90Y-microspheres in 548 patients with colorectal liver metastases progressing on systemic chemotherapy.

C. Nutting, S. Rose, Steven J. Cohen, 2013 .

Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer.

F. Khuri, W. Hong, J. Roth, 1999, Journal of the National Cancer Institute.

Growth suppression of human leukemic cells in vitro by L-ascorbic acid.

B. Hoogstraten, M. Savin, C. Park, 1980, Cancer research.

Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography predicts extrahepatic metastatic potential of colorectal metastasis: a practical guide for yttrium-90 microsphere liver-directed therapy.

J. Thie, R. Salem, Chilai Ho, 2010, Cancer biotherapy & radiopharmaceuticals.

Regulation of Homocysteine Biosynthesis in Salmonella typhimurium

M. Savin, M. Flavin, C. Slaughter, 1972, Journal of bacteriology.

Quantitative measurement of HER2 expression in breast cancers: comparison with ‘real-world’ routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival

John W. Adams, L. Bosserman, D. Yardley, 2015, Breast Cancer Research.

SNPs in the transforming growth factor-β pathway as predictors of outcome in advanced lung adenocarcinoma with EGFR mutations treated with gefitinib

M. Savin, R. Ruxer, R. Yanagihara, 2014 .

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.

L. R. Hill, F. Holmes, J. O’Shaughnessy, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Regional yttrium-90 microsphere treatment of surgically unresectable and chemotherapy-refractory metastatic liver carcinoma.

J. Thie, R. Salem, C. Wong, 2006, Cancer biotherapy & radiopharmaceuticals.

Pemetrexed in Relapsed Small-Cell Lung Cancer and the Impact of Shortened Vitamin Supplementation Lead-In Time: Results of a Phase II Trial

David A. Smith, C. Obasaju, M. Socinski, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

F. Holmes, J. O’Shaughnessy, J. Pippen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer.

G. Clark, J. Pippen, Stephen E. Jones, 2002, Clinical breast cancer.

Low proliferative rate of invasive node-negative breast cancer predicts for a favorable outcome: a prospective evaluation of 669 patients.

G. Clark, J. Pippen, R. Mennel, 2001, Clinical breast cancer.

A pilot study of intraarterial chemotherapy with cisplatin in locally advanced head and neck cancers

M. Savin, J. Regan, Dominic K. Cheung, 1988, Cancer.

Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy.

D. Royall, D. V. Von Hoff, F. Holmes, 2005, Clinical breast cancer.

Radiation microsphere-induced GI ulcers after selective internal radiation therapy for hepatic tumors: an underrecognized clinical entity.

M. Cappell, M. Savin, M. Duffy, 2009, Gastrointestinal endoscopy.

John W. Adams, L. Bosserman, D. Yardley, 2015, Breast Cancer Research.

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

V. Gebski, P. Gibbs, F. Lammert, 2017, The Lancet. Oncology.

Hepatopulmonary Shunting: A Prognostic Indicator of Survival in Patients with Metastatic Colorectal Adenocarcinoma Treated with 90Y Radioembolization.

C. Hoh, C. Nutting, S. Rose, 2017, Radiology.

Everolimus plus exemestane treatment in metastatic hormone receptor-positive breast cancer patients previously treated with CDK4/6 inhibitor therapy.

M. Savin, A. Kaempf, Z. Mitri, 2020, The oncologist.

Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases.

C. Nutting, S. Rose, D. Coldwell, 2015, Journal of gastrointestinal oncology.

Phase II evaluation of carboplatin and VP‐16 for patients with metastatic breast cancer and only one prior chemotherapy regimen

Stephen E. Jones, R. Mennel, M. Savin, 1993, Cancer.

Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for (90)Y resin microspheres.

C. Nutting, S. Rose, D. Coldwell, 2015, Journal of gastrointestinal oncology.

Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.

N. Robert, J. O’Shaughnessy, J. Pippen, 2007, Clinical breast cancer.

Patient-reported and objectively measured physical function in older breast cancer survivors and cancer-free controls.

K. Winters-Stone, M. Savin, M. Medysky, 2019, Journal of geriatric oncology.

Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced non-small cell lung cancer (NSCLC)

N. Iannotti, N. Gabrail, A. Spira, 2007 .

Cystathionine Synthesis in Yeast: an Alternative Pathway for Homocysteine Biosynthesis

M. Savin, M. Flavin, 1972, Journal of bacteriology.

A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.

A. Das, N. Iannotti, N. Gabrail, 2012, Clinical lung cancer.